Given the CART cell-mediated leakage of tumor cells lacking the target Ag and considering the potential of STING agonists to prompt a host’s immune response,23 we wondered whether the combination of CART cells with the intratumoral administration of a STING-L might promote an endogenous T-cell response that counteracts tumor escape from CART cells. The gene discussed is STING1; the disease is neoplasm.